Indian biopharma company Intas has become the first Indian company to launch a biosimilar in highly regulated territories such as the European Union, the USA and Japan.
Its biosimilar, filgrastim, has been launched in Europe through Intas’ wholly-owned subsidiary Accord Healthcare, under the name Accofil.
Intas is also the only Indian company to have two of its products, filgrastim and peg-filgrastim, filed for registration in the USA, through its partner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze